Imaging of Prostate-Specific Membrane Antigen Using [18F]DCFPyL

Steven P. Rowe, Michael A. Gorin, Martin G. Pomper

Research output: Contribution to journalReview articlepeer-review


Prostate-specific membrane antigen (PSMA) has been explored as a target for molecular imaging of prostate cancer and other malignancies that express PSMA in their tumor-associated neovasculature. Although several PSMA-targeted radiotracers labeled with a variety of radionuclides have been reported, positron-emitting radiotracers labeled with 18F are of particular interest. One such compound, the small molecule PSMA inhibitor [18F]DCFPyL, has demonstrated initial success. This article reviews the literature on this radiotracer, including radiosynthetic approaches to the molecule, data that are available from preclinical experiments, and evidence to date of the clinical utility of this agent in prostate cancer and clear cell renal cell carcinoma.

Original languageEnglish (US)
Pages (from-to)289-296
Number of pages8
JournalPET Clinics
Issue number3
StatePublished - Jul 2017


  • DCFPyL
  • Prostate cancer
  • Radiopharmaceutical

ASJC Scopus subject areas

  • Radiation
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Imaging of Prostate-Specific Membrane Antigen Using [18F]DCFPyL'. Together they form a unique fingerprint.

Cite this